Payment overview · 2025
General Payments
$612.75
29 reported records · 17 companies
Healthcare provider profile · identity verified
James Beach, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PHOENIX, AZ · NPI 1053304808
Verified facts
What the public records show
CMS Open Payments records show James Beach, D.O. received $612.75 in general payments during 2025 across 29 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $157.50 | 25.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.86 | 8.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.17 | 7.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.28 | 6.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.44 | 6.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.81 | 6.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.36 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.89 | 5.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $30.82 | 5.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.22 | 4.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.49 | 3.5% | 1 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $20.92 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.30 | 3.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.80 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.30 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.59 | 2.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.00 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $612.75 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $157.50 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $54.87 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.17 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $38.44 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.89 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $30.82 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
144 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 742 | 214 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 581 | 179 |
| Lisinopril | Lisinopril | 451 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 110 |
| Metformin Hcl | Metformin Hcl | 398 | 124 |
| Gabapentin | Gabapentin | 328 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 79 |
| Losartan Potassium | Losartan Potassium | 227 | 62 |
| Omeprazole | Omeprazole | 223 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 64 |
| Furosemide | Furosemide | 214 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 54 |
| Trazodone Hcl | Trazodone Hcl | 181 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 57 |
| Famotidine | Famotidine | 160 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 44 |
| Mounjaro | Tirzepatide | 144 | 27 |
| Buspirone Hcl | Buspirone Hcl | 130 | 28 |
| Alendronate Sodium | Alendronate Sodium | 127 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 30 |
| Valsartan | Valsartan | 118 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 109 | 25 |
| Simvastatin | Simvastatin | 109 | 29 |
| Ozempic | Semaglutide | 108 | 26 |
| Allopurinol | Allopurinol | 106 | 28 |
| Ibuprofen | Ibuprofen | 104 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 104 | suppressed |
| Trulicity | Dulaglutide | 104 | 26 |
| Eliquis | Apixaban | 103 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 30 |
| Jardiance | Empagliflozin | 102 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 22 |
| Meloxicam | Meloxicam | 89 | 27 |
| Carvedilol | Carvedilol | 84 | 29 |
| Finasteride | Finasteride | 84 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 25 |
| Glimepiride | Glimepiride | 79 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 14 |
| Montelukast Sodium | Montelukast Sodium | 68 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 65 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 13 |
| Pregabalin | Pregabalin | 60 | 16 |
| Potassium Chloride | Potassium Chloride | 56 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Verapamil Er | Verapamil Hcl | 55 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 16 |
| Midodrine Hcl | Midodrine Hcl | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | suppressed |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 11 |
| Atenolol | Atenolol | 48 | 16 |
| Tramadol Hcl | Tramadol Hcl | 47 | 13 |
| Sertraline Hcl | Sertraline Hcl | 46 | 11 |
| Ezetimibe | Ezetimibe | 45 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 17 |
| Ondansetron Odt | Ondansetron | 43 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 11 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 25 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Naproxen | Naproxen | 30 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 13 |
| Azithromycin | Azithromycin | 28 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | 12 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Captopril | Captopril | 14 | suppressed |
| Dasetta | Norethindrone-Ethin. Estradiol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $612.75 · 29 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, CREON, FARXIGA, INSPIRE, JARDIANCE, Kerendia, Leqembi, MINIMED 780G, Omnipod, PAXLOVID, PROCLAIM, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, Xeomin, ZENPEP | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error